Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
PEA wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
2 of 3 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
6 of 6 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both MSM and PEA have evidence — compare verdict strength side-by-side.
2-3g
With meals, Split into 2-3 doses
Powder or capsules
600-1200mg
With meals, Split into 2-3 doses
Micronized or ultra-micronized PEA
4-12 weeks
2-4 weeks
8-12 weeks
2-8 weeks
4-8 weeks
Ongoing
Effects of dietary supplements on patients with osteoarthritis: A systematic review and network meta-analysis
Journal of integrative medicine (2025) · Meta analysis · n=2455
In the WOMAC pain score, the SUCRA of passion fruit peel extract was 91% (mean difference [MD]: -9.2; 95% confidence interval [CI]: [-16.0, -2.3]), followed by methylsulfonylmethane (89%), undenatured type II collagen (87%), collagen (84%), and Lanconone (82%).
Methylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial
Nutrients (2023) · Rct · n=88
The total scores at 12 weeks in the MSM and placebo groups as the primary outcome were significantly different (p = 0.046).
The Effect of Daily Methylsulfonylmethane (MSM) Consumption on High-Density Lipoprotein Cholesterol in Healthy Overweight and Obese Adults: A Randomized Controlled Trial
Nutrients (2021) · Rct · n=22
The primary finding of this work shows that high-density lipoprotein cholesterol was elevated at 8 and 16 weeks of daily MSM consumption compared to baseline, (p = 0.008, p = 0.013).
Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis
Nutrients (2024) · Meta analysis · n=742
These two obtained scores corresponded to a 35.1% pain intensity reduction within the first month, followed by a further 35.4% during the second month.
Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials
Nutrients (2023) · Meta analysis · n=774
PEA was found to reduce pain scores relative to comparators in a pooled estimate, with a standard mean difference of 1.68 (95% CI 1.05 to 2.31, p = 0.00001).
Navigating agitation in neurodevelopmental disorders: A comparative study of pharmacotherapies via network meta-analysis in children and adults with autism spectrum disorder or intellectual disabilities
Journal of psychopharmacology (Oxford, England) (2025) · Meta analysis · n=2503
Importantly, these treatments were generally well-tolerated, with no significant increase in all-cause dropouts compared to placebo, highlighting their suitability for clinical use in managing agitation in individuals with ASD or ID.
Based on limited RCT evidence. One 12-week study (n=88) showed significant improvement in knee pain scores. Conservative effectiveness estimate given small study size and limited replication.
Based on multiple meta-analyses showing ~35% pain reduction. Studies primarily used micronized formulations which may have better bioavailability than standard forms. Most benefits observed within 4-6 weeks of treatment.
AI-estimated from published studies. Interpret as directional guidance.
PEA has a higher evidence score (7.5/10 vs 6/10) and wins in 2 of 3 categories.
For reduce inflammation, PEA has a higher relevance score (85 vs 80).
No known interactions between MSM and PEA have been documented in our database. However, always consult a healthcare provider before combining supplements.